MX2019006631A - Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas. - Google Patents

Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas.

Info

Publication number
MX2019006631A
MX2019006631A MX2019006631A MX2019006631A MX2019006631A MX 2019006631 A MX2019006631 A MX 2019006631A MX 2019006631 A MX2019006631 A MX 2019006631A MX 2019006631 A MX2019006631 A MX 2019006631A MX 2019006631 A MX2019006631 A MX 2019006631A
Authority
MX
Mexico
Prior art keywords
cells
drug
nucleic acid
transcription factor
inducible
Prior art date
Application number
MX2019006631A
Other languages
English (en)
Spanish (es)
Inventor
C Jensen Michael
Ooi Tracy
Wei Jia
Original Assignee
Seattle Childrens Hospital Dba Seattle Childrens Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Hospital Dba Seattle Childrens Res Inst filed Critical Seattle Childrens Hospital Dba Seattle Childrens Res Inst
Publication of MX2019006631A publication Critical patent/MX2019006631A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
MX2019006631A 2016-12-12 2017-12-11 Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas. MX2019006631A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662433183P 2016-12-12 2016-12-12
PCT/US2017/065597 WO2018111763A1 (en) 2016-12-12 2017-12-11 Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells

Publications (1)

Publication Number Publication Date
MX2019006631A true MX2019006631A (es) 2019-11-12

Family

ID=62559136

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006631A MX2019006631A (es) 2016-12-12 2017-12-11 Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas.

Country Status (8)

Country Link
US (2) US11408005B2 (OSRAM)
EP (1) EP3551197B1 (OSRAM)
JP (2) JP7091357B2 (OSRAM)
CN (1) CN110291200B (OSRAM)
AU (1) AU2017375630B2 (OSRAM)
CA (1) CA3045665A1 (OSRAM)
MX (1) MX2019006631A (OSRAM)
WO (1) WO2018111763A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US10611837B2 (en) 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
CA3045665A1 (en) 2016-12-12 2018-06-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
US10561686B2 (en) 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
CN111936518A (zh) * 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
TWI809130B (zh) 2018-06-22 2023-07-21 美商凱特製藥公司 嵌合跨膜蛋白及其用途
KR20210043562A (ko) * 2018-07-10 2021-04-21 프레시전 인코포레이티드 Ror-1 특이적 키메라 항원 수용체 및 그의 용도
EP3845564A4 (en) * 2018-08-28 2022-05-18 Immunotech Biopharm Co., Ltd. ENHANCED THERAPEUTIC T LYMPHOCYTE
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
JP6821230B2 (ja) 2019-02-04 2021-01-27 国立大学法人愛媛大学 ＣＡＲライブラリおよびｓｃＦｖの製造方法
WO2020183131A1 (en) * 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
JP2022525400A (ja) * 2019-03-13 2022-05-13 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） フルオレセインエーテルリン脂質またはフルオレセインエーテルリン脂質前駆体と併用した抗フルオレセインｃａｒ ｔ細胞に対する拮抗薬としてのフルオレセインナトリウム
US20220195441A1 (en) * 2019-04-25 2022-06-23 Seattle Children's Hospital (dba Seattle Children's Research Institute) Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias
JP2022536975A (ja) * 2019-06-21 2022-08-22 カイト ファーマ インコーポレイテッド ＴＧＦ－β受容体及び使用方法
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
WO2021231569A1 (en) * 2020-05-14 2021-11-18 Seattle Children's Hospital (dba Seattle Children's Research Institute) Dual promoter systems
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
EP4161537A4 (en) * 2020-06-08 2024-07-03 Seattle Children's Hospital (DBA Seattle Children's Research Institute) ANTI-CD171 CHIMERIC ANTIGEN RECEPTORS
CN111848819A (zh) * 2020-07-31 2020-10-30 广东昭泰体内生物医药科技有限公司 一种靶向msln的嵌合抗原受体及其应用
JP2023545071A (ja) * 2020-10-09 2023-10-26 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） Ｐｄ１キメラポリペプチドを含む方法および組成物
EP4259648A4 (en) * 2020-12-08 2025-03-26 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Chimeric anti-EGFR antigen receptors
WO2022174035A2 (en) * 2021-02-12 2022-08-18 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Activity-inducible fusion proteins having a heat shock protein 90 binding domain
WO2022221592A2 (en) * 2021-04-15 2022-10-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for producing and using cell-based immunotherapies to target tumors
US20250074959A1 (en) * 2021-05-14 2025-03-06 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Activity-inducible fusion proteins having a transcription factor and a heat shock protein 90 binding domain
CN116589585B (zh) * 2021-12-29 2023-11-24 华道(上海)生物医药有限公司 一种抗IL13Ra2的纳米抗体及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2096222C (en) 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
US20020111474A1 (en) 1990-12-14 2002-08-15 Capon Daniel J. Chimeric chains for receptor-associated signal transduction pathways
JPH07507278A (ja) 1992-06-01 1995-08-10 ニューイングランド　メディカル　センター　ホスピタルズ　インク Ｃｄ４３キメラ分子による細胞間相互作用の阻害
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6133027A (en) * 1996-08-07 2000-10-17 City Of Hope Inducible expression system
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
GB0015119D0 (en) 2000-06-20 2000-08-09 Angeletti P Ist Richerche Bio Methods and means for regulation of gene expression
US20020106729A1 (en) 2000-07-03 2002-08-08 Bleck Gregory T. Expression vectors
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
WO2002097099A1 (en) 2001-05-29 2002-12-05 Valentis, Inc. Regulated expression of ghrh
US7381813B2 (en) * 2001-05-31 2008-06-03 Novartis Ag Nucleic acids encoding estrogen receptor ligand binding domain variants
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
US20030228606A1 (en) 2002-04-11 2003-12-11 Amgen Inc., A Corporation Of The State Of Delaware Her-2 receptor tyrosine kinase molecules and uses thereof
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2004092338A2 (en) 2003-04-11 2004-10-28 Diadexus, Inc. Compositions, splice variants and methods relating to cancer specific genes and proteins
US20070166318A1 (en) 2003-05-30 2007-07-19 Macina Roberto A Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
RU2397249C2 (ru) 2003-07-21 2010-08-20 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа СИНТЕТИЧЕСКАЯ МОЛЕКУЛА НУКЛЕИНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР ДЛЯ КЛЕТОК МЛЕКОПИТАЮЩЕГО, КЛЕТКА МЛЕКОПИТАЮЩЕГО ХОЗЯИНА И СПОСОБ ЭКСПРЕССИИ ЧЕЛОВЕЧЕСКОГО БЕЛКА АНТИГЕНА ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА-2 (HER2/neu) ИЛИ ЕГО УКОРОЧЕННОЙ ФОРМЫ
EP1680447A2 (en) 2003-10-24 2006-07-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Orthogonal gene switches
WO2005062881A2 (en) 2003-12-24 2005-07-14 Transgenrx, Inc. Gene therapy using transposon-based vectors
US7935510B2 (en) * 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
JP2009521474A (ja) 2005-12-21 2009-06-04 メディミューン，エルエルシー ＥｐｈＡ２ＢｉＴＥ分子およびその使用
US8148129B2 (en) * 2006-06-30 2012-04-03 The Regents Of The University Of California Generation of potent dominant negative transcriptional inhibitors
WO2008012237A1 (en) 2006-07-24 2008-01-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Multi-antigen construct and uses thereof
US7709253B2 (en) 2006-08-04 2010-05-04 The Board Of Trustees Of The Leland Stanford Junior University Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
DK2279253T3 (en) 2008-04-09 2017-02-13 Maxcyte Inc Construction and application of therapeutic compositions of freshly isolated cells
US8822647B2 (en) 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CN102227503B (zh) 2008-09-26 2015-10-21 托卡根公司 重组载体
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
WO2010141543A1 (en) 2009-06-02 2010-12-09 Targeted Molecular Diagnostics, Llc Methods for the detection and quantitation of the p95 component of her2/neu (erbb2)
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
CA2779526C (en) 2009-11-03 2022-12-06 City Of Hope Truncated epiderimal growth factor receptor (egfrt) for transduced t cell selection
JP5285678B2 (ja) 2010-06-18 2013-09-11 株式会社エヌ・ティ・ティ・ドコモ 移動通信方法及びコアネットワーク装置
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012099973A2 (en) 2011-01-18 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
CN110200997A (zh) 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
CN103502439B (zh) 2011-04-13 2016-10-12 因缪尼卡姆股份公司 用于抗原特异性t细胞增殖的方法
BR112013029746B1 (pt) 2011-06-22 2021-02-02 F. Hoffmann-La Roche Ag método para a produção recombinante de um complexo, complexo, formulação farmacêutica e uso do complexo
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
ITRM20120058A1 (it) 2012-02-20 2013-08-21 Pisanelli Giovanni Codacci Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione
CA3205751A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
MX394639B (es) 2012-04-11 2025-03-24 Us Health Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
WO2013177533A1 (en) 2012-05-25 2013-11-28 California Institute Of Technology Expression of secreted and cell-surface polypeptides
US20150376645A1 (en) 2012-05-30 2015-12-31 Baylor College Of Medicine Supercoiled minivectors as a tool for dna repair, alteration and replacement
EP2669378A1 (en) 2012-05-31 2013-12-04 Helmut Hanenberg Cytochrome P450 suicide gene system
JP6079775B2 (ja) 2012-06-01 2017-02-15 日本電気株式会社 スイッチングシステム、ラインカード、スイッチカード、ｆｄｂ学習方法、ｆｄｂ学習調停方法及びプログラム
IL293944A (en) 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
US10316289B2 (en) 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
CN104853766A (zh) 2012-10-02 2015-08-19 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
WO2014138704A1 (en) 2013-03-07 2014-09-12 Baylor College Of Medicine Targeting cd138 in cancer
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
DK3071222T3 (da) 2013-11-21 2020-11-16 Ucl Business Ltd Celle
AU2014368383B2 (en) 2013-12-20 2020-01-16 Cellectis Method of engineering multi-input signal sensitive T cell for immunotherapy
ES2767423T3 (es) 2014-01-13 2020-06-17 Hope City Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
US10611837B2 (en) * 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
AU2017213661B2 (en) 2016-02-05 2022-06-02 City Of Hope Administration of engineered T cells for treatment of cancers in the central nervous system
CA3045665A1 (en) 2016-12-12 2018-06-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells

Also Published As

Publication number Publication date
AU2017375630B2 (en) 2023-12-21
JP2020500563A (ja) 2020-01-16
CN110291200A (zh) 2019-09-27
JP7091357B2 (ja) 2022-06-27
US20220411805A1 (en) 2022-12-29
EP3551197B1 (en) 2023-11-22
WO2018111763A9 (en) 2018-07-19
EP3551197A1 (en) 2019-10-16
US20200181624A1 (en) 2020-06-11
JP2022130485A (ja) 2022-09-06
EP3551197A4 (en) 2020-10-28
JP7392043B2 (ja) 2023-12-05
AU2017375630A1 (en) 2019-06-13
US11408005B2 (en) 2022-08-09
CA3045665A1 (en) 2018-06-21
WO2018111763A1 (en) 2018-06-21
CN110291200B (zh) 2024-05-14

Similar Documents

Publication Publication Date Title
MX2019006631A (es) Variantes quimericas de factores de transcripcion con sensibilidad aumentada a induccion por ligando de farmaco de expresion transgenica en celulas mamiferas.
CY1120980T1 (el) Μεθοδοι παρασκευης για τον ελεγχο της περιεκτικοτητας σε c-τελικη λυσινη, γαλακτοζη και σιαλικο οξυ σε ανασυνδυασμενες πρωτεϊνες
CY1122833T1 (el) Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7
EA201891092A1 (ru) Способы и композиции для редактирования генов в гемопоэтических стволовых клетках
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
MX2020013977A (es) Proteínas quiméricas transmembrana y usos de las mismas.
BR112012017896A2 (pt) Excisão de transgenes em organismos geneticamente modificados
RU2019127316A (ru) Рнк-направляемая инженерия генома человека
ES2743232T3 (es) Métodos para la activación o eliminación controlada de células terapéuticas
RU2020103811A (ru) Гуманизированные животные по с5 и с3
HRP20191907T1 (hr) 3´utr sekvence za stabilizaciju rnk
RU2017134741A (ru) Полипептиды транспозазы и их применение
EA201891681A1 (ru) Новая иммуностимулирующая векторная система
CL2009000123A1 (es) Anticuerpo humanizado o fragmento de union del mismo especifico para el factor von willebrand (vwf); acido nucleico codificante; vector y celulas huesped; metodo para producir dicho anticuerpo humanizado; composicion que lo comprende; uso medico del mismo para tratar un trastorno mediado por vwf; usos no terapeuticos
AR084208A1 (es) Moduladores del ligando de efrina a (efna) y metodos para su uso
CL2014001317A1 (es) Polipeptido aislado que tiene actividad de lisozima; polinucleotido aislado que lo codifica; construccion de acido nucleico o vector de expresion; celula huesped recombinante; metodo de produccion; composicion que lo comprende, ya sea detergente o de alimentacion animal o aditivo de alimentacion animal; y su uso.
PE20170261A1 (es) Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos
MX2015016798A (es) Regulacion transcripcional guiada por acido ribonucleico.
AR097493A1 (es) Constructos para expresar transgenes con el uso de elementos reguladores provenientes de genes ubiquitina de brachypodium
RU2019124678A (ru) Слитый белок pd1-41bbl и способы его применения
BR112016015424A2 (pt) planta transgênica; polinucleotídeo recombinante; vetor de expressão expressável em plantas; método para a produção de uma planta transformada tendo fotossíntese aprimorada; e proteína quimérica
EA201590747A1 (ru) Способы лечения с использованием аденовируса
BR112019024656A2 (pt) vírus oncolíticos para a sensibilização de células tumorais para morte por células exterminadoras naturais
AR095982A1 (es) Factores de transcripción artificiales modificados genéticamente para superar el atrapamiento endosómico
WO2013177593A3 (en) Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies